Onconetix (J4T0) Stock Overview
A biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, European Union, and Non-European Union. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
J4T0 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Onconetix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.82 |
| 52 Week High | US$10.66 |
| 52 Week Low | US$2.74 |
| Beta | 3.25 |
| 1 Month Change | 0% |
| 3 Month Change | -27.32% |
| 1 Year Change | -58.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| J4T0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | 2.6% |
| 1Y | -58.3% | -30.1% | 12.4% |
Return vs Industry: J4T0 underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: J4T0 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| J4T0 volatility | |
|---|---|
| J4T0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: J4T0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine J4T0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Ralph Schiess | www.onconetix.com |
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023.
Onconetix, Inc. Fundamentals Summary
| J4T0 fundamental statistics | |
|---|---|
| Market cap | €2.76m |
| Earnings (TTM) | -€49.46m |
| Revenue (TTM) | €1.79m |
Is J4T0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J4T0 income statement (TTM) | |
|---|---|
| Revenue | US$1.87m |
| Cost of Revenue | US$2.60m |
| Gross Profit | -US$732.03k |
| Other Expenses | US$50.87m |
| Earnings | -US$51.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.22 |
| Gross Margin | -39.13% |
| Net Profit Margin | -2,758.66% |
| Debt/Equity Ratio | 24.3% |
How did J4T0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 00:55 |
| End of Day Share Price | 2024/09/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Onconetix, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vernon Bernardino | H.C. Wainwright & Co. |
| Jason McCarthy | Maxim Group |